Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Financing Business Strategies Neurology

NeuroPace Seeks $75M In IPO

  • News

Executive Summary

The California neuromodulation company filed a registration with the US Securities and Exchange Commission to sell common stock on NASDAQ under the ticker NPCE.

You may also be interested in...



NeuroPace Raises $67M To Help Commercialize RNS System For Epilepsy

The latest financing round will also support a new clinical trial of the RNS system for children with epilepsy.

AMA Establishes Principles For ‘Augmented Intelligence’

The American Medical Association has written a set of principles for augmented intelligence (AI) development and deployment in health care. The organization hopes these principles can shape “a consistent governance structure for advancements in health care technology.”

News We’re Watching: Boston Scientific Closes Relievant, Medtronic's PFA Earns CE Mark, And More

Medtech Insight's News We're Watching highlights medtech industry news developments you may have missed over the last few weeks.

Table

View full table

Topics

Tags:
Financing Business Strategies Neurology
Latest Headlines

Medtech Industry Weighs In On EMA’s AI Regulation Proposals

Medtech Advocate Announces Retirement From House Of Representatives

More Nightmares For Philips DreamStation Machines

Latest Notified Body Designated Under the EU’s MDR Is A Software Specialist

See All
UsernamePublicRestriction

Register

MT143709

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By